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Abstract 
Background: Immunoglobulin E (IgE) is the treatment target of omalizumab, a monoclonal antibody indicated in 
the treatment of severe allergic asthma. Long-term variability of serum total IgE  (sIgEtot) in asthmatics remains poorly 
documented.
Methods: In this prospective study,  sIgEtot levels were measured over 1 year at 7 time points in 41 severe asthmatics 
treated with high-dose of inhaled corticosteroids and long-acting β2 agonists. 33 patients were atopic based on at 
least one positive RAST to common aeroallergens. Patients were divided into three groups according to their baseline 
 sIgEtot level: low (< 76 IU/mL; n = 10), intermediate (76–700 IU/mL; n = 20) or high (> 700 IU/mL; n = 11). Patients also 
completed the six-item Juniper Asthma Control Questionnaire  (ACQ6). The  sIgEtot variability and factors predictive for 
this variability were studied, as well as  ACQ6 outcomes.
Results: The variation in  sIgEtot level was mostly the consequence of between patient-variability, which represented 
96%, 71% and 96% of the total variability in the low, intermediate and high  sIgEtot subgroups, respectively. The 
residual within-patient variability was therefore limited. In 10/41 patients,  sIgEtot levels increased or decreased, for at 
least one visit, beyond the predefined range of the subgroups to which they were assigned (< 76 IU/mL; 76–700 IU/
mL; > 700 IU/mL). There was a significant but weak correlation between  sIgEtot and  ACQ6 score over all time points 
(r = 0.15, p = 0.02), but  sIgEtot failed to associate with severe exacerbation.  sIgEtot decreased by 3% with any additional 
year of age for the whole group (p = 0.01) and increased by 5% per one unit of allergen exposure score in atopic 
patients (p = 0.002).
Conclusion: In severe asthmatics, limited within-patient variability of  sIgEtot levels was observed over 1 year as 
opposed to marked between-subject variability.  sIgEtot decreases with age. Variation in  sIgEtot weakly associates with 
asthma control but not with exacerbation.
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Introduction
Immunoglobulin E (IgE) is an antibody associated with 
hypersensitivity and allergic reactions. IgE mainly binds 
on the high-affinity IgE receptor (FcεRI) on mast cells 
and basophils. Upon FcεRI cross-linking following 
allergen exposure, inflammatory mediators including 
histamine, leukotrienes and pro-inflammatory cytokines 
are released [1]. However, in murine models, the binding 
of IgE itself on mast cell surface may already favour cell 
survival and cytokine release irrespective of the presence 
of any allergen [2, 3]. Although direct evidence for this 
is still lacking in humans, it has been reported that 
asthmatics with high sputum IgE levels have also raised 
sputum levels of TNFα and Interleukin-6, two cytokines 
released from mast cells [4]. Therefore, IgE might possibly 
be considered as an inflammatory mediator independent 
of atopic status and deserves to be monitored.
In a study of a community population with 
measurements at two time points over an 8-year period, 
the level of serum total IgE  (sIgEtot) tended to be stable in 
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subjects above the age of 35 years while levels decreased 
in children and young adults. Atopic subjects tended to 
show a decrease with age even after the age of 35 years 
[5]. Further, a longitudinal study spanning a period of 
up to 20  years also showed that smoking opposed the 
natural decline in IgE and synergized with atopy to result 
in increased levels in subjects over the age of 50  years 
[6]. However, variation in  sIgEtot beyond two or three 
time points in the same subject has not been studied 
extensively.
Omalizumab, a monoclonal antibody that binds 
serum IgE, has become part of asthma treatment for the 
severe spectrum of the disease in which patients remain 
uncontrolled despite a combination of high dose inhaled 
corticosteroids (ICS) with long-acting β2 agonist (LABA). 
The drug has been validated in asthmatics whose serum 
IgE ranges from 30 to 700 IU/mL but most of the effect 
in terms of reduction of exacerbation was confined to 
patients with serum IgE ranging from 76 to 700  IU/mL 
[7]. A retrospective chart review of severe asthmatics 
with two to four measurements of  sIgEtot over an average 
period of 2  years showed some clinically significant 
variability in  sIgEtot affecting candidacy and dosing of 
omalizumab [8]. A recent prospective study conducted 
with 17 moderate-to-severe asthma patients with 6 serial 
measurements confirmed this variability in  sIgEtot over 
1 year [9].
To better understand  sIgEtot variation and factors 
influencing this variation, we conducted a 12-month 
prospective study of  sIgEtot levels in severe asthmatics 
treated with high-dose ICS and LABA. Furthermore, 
we also examined how fluctuation in IgE may relate to 




Patients enrolled in the study had an established 
diagnosis of severe asthma as defined by the ERS/ATS 
consensus statement [10], aged ≥ 18 years, and currently 
treated with high-dose ICS (daily dose of fluticasone 
propionate > 500 µg or equivalent) and a LABA. Patients 
were excluded from the study if: (i) they were being or 
had been treated with omalizumab  (Xolair®, Novartis, 
Basel, Switzerland), unless treatment was stopped at 
least 1  year before inclusion; (ii) they were undergoing 
immunotherapy; and/or (iii) used an investigational 
drug at the time of enrollment or within 30 days prior to 
enrollment in the study.
Study design
This was a prospective, multicenter study to assess 
variability of  sIgEtot levels in severe asthmatics conducted 
in 5 Belgian centers. The 12-month variability in  sIgEtot 
levels in the total population was assessed and the 
proportion of the total variability explained by within- 
and between-patient variability was calculated (primary 
objective). In accordance with reimbursement criteria 
in Belgium, patients were stratified post hoc into three 
groups on the basis of baseline  sIgEtot: < 76  IU/mL (low 
IgE), 76–700  IU/mL (intermediate IgE), and > 700  IU/
mL (high IgE). These three groups were selected based 
on the study of Bousquet et  al., which demonstrated 
that omalizumab reduces the annualized rate of asthma 
exacerbations more in patients with  sIgEtot ≥ 76  IU/mL 
[7]; and based on the upper limit of serum IgE inclusion 
criteria of the INNOVATE registration study (< 700  IU/
mL) [11]. These two studies are currently used as the 
basis for the reimbursement of omalizumab in Belgium. 
An additional objective of the study was to evaluate 
demographic, environmental, and treatment factors that 
may influence  sIgEtot variation and whether  sIgEtot relates 
to asthma control and asthma exacerbation.
At baseline patients completed the six-item Juniper 
Asthma Control Questionnaire  (ACQ6) [12]; blood was 
sampled to measure  sIgEtot levels; and atopic status of 
the patient was evaluated with a radio allergosorbent test 
(RAST) directed towards common allergens: grass mix, 
birch, mould mix, house dust mite (Dermatophagoides 
pteronyssinus), and cat and dog dander. Patients were 
considered atopic if RAST levels to any allergen exceeded 
0.35 kU/L. Additionally, an environmental questionnaire 
was completed which enquired about the frequency of 
patients’ exposure (1: “once, more than 1 month ago”; 2: 
“once, more than 1  week ago”; 3: “once, within the last 
week”; 4: “occasionally”; 5: “frequently” or 6: “constantly”) 
to house dusts, pollens, molds, cats and dogs, smoke, 
humidifier/vaporizer, and carpeting.
Subsequently, 6 visits were planned every 2 months for 
a follow-up period of 12 months. At each visit,  sIgEtot was 
measured, the  ACQ6 and environmental questionnaires 
were completed, and the treatment prescribed by the 
physician was registered. Treatment prescription, 
continuation, or discontinuation was per the physician’s 
best clinical judgment and in accordance with the Belgian 
reimbursement criteria. Also, to allow for the monitoring 
of exacerbations during the study, patients had to report 
if and how many times they had an exacerbation since 
the last visit. The presence of an exacerbation in the week 
preceding the visit was recorded specifically. A severe 
exacerbation was defined as an exacerbation requiring a 
treatment containing systemic corticosteroids for at least 
three consecutive days and/or an emergency room visit 
and/or a hospitalization.
This study was approved by the ethical committee of 
the CHU Liege under approval number B70720096731. 
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All patients had to provide an informed consent before 
entering the study.
Statistical analysis
Descriptive statistics were calculated using frequencies, 
percentages, means, standard deviations, medians 
and ranges as appropriate. Comparisons in baseline 
characteristics between the three subgroups (low, 
intermediate, high  sIgEtot) were tested using ANOVA 
with Tukey post hoc test comparison for age and 
a general linear model with contrasts for other 
(categorical) variables. Random-intercepts regression 
analysis was used to model log-transformed  sIgEtot, with 
‘patient’ as the random variable. The model allowed us 
to calculate intra-cluster correlations to determine how 
much of the variability observed in  sIgEtot levels over 
time could be attributed to variability between individual 
patients, compared to variability within each patient. 
It also allowed us to test predictors of  sIgEtot (exposure 
to allergens, active/passive exposure to tobacco smoke, 
change in asthma treatment, treatment with maintenance 
systemic corticosteroids, and  ACQ6 score). Modeling 
of exacerbations (absent/present) was performed by 
logistic regression analysis, using generalized estimating 
equations to account for repeated measurements over 
time. This analysis was used to assess influence of 
treatment changes and time of year. The correlation 
between  sIgEtot and  ACQ6 score at baseline was evaluated 
with a Spearman correlation. As this was a real-life 
study, data were collected from routine clinical practice 
and there may be missing data. Missing values were not 
imputed in the descriptive and statistical analyses. p 
values < 0.05 were considered statistically significant.
Results
Patient characteristics
In total, 41 patients were recruited. The median  sIgEtot 
level at baseline in the entire study group was 248  IU/
mL (range 17–7620  IU/mL). Mean  ACQ6 score was 
1.5 ± 0.87. Only 14/39 patients (35%; 2 responses 
unknown) had asthma GINA-defined as controlled at 
baseline. Of these 41 patients, 10 (27%) were included in 
the low  sIgEtot subgroup (≤ 76  IU/mL; median baseline 
 sIgEtot = 43.5  IU/mL, range 17–71  IU/mL); 20 patients 
(49%) were included in the intermediate  sIgEtot subgroup 
(76–700 IU/mL; median baseline  sIgEtot level = 247.0 IU/
mL (range 86–667  IU/mL); and 11 patients (24%) were 
included in the high  sIgEtot subgroup (> 700  IU/mL; 
median baseline  sIgEtot level = 1332.0  IU/mL, range 
729–7620 IU/mL). Atopy, defined as a positive RAST to 
at least one common aeroallergen, was present in 33/41 
subjects (80%). The baseline characteristics by subgroup 
are given in Table 1.
Variability in  sIgEtot over 12 months
The between-patient variability represented 93.4% of 
the total variability for the entire sample, and 96%, 
71% and 96% in the low, intermediate, and high  sIgEtot 
subgroups, respectively. Therefore, within-patient 
variability represented 4%, 29% and 4% of the total 
variability in the low, intermediate and high  sIgEtot 
subgroups, respectively. The within-patient variability 
was significantly higher in the intermediate  sIgEtot group 
than in the other groups (p < 0.0001) (Table 2).
Detailed individual trajectories over time by baseline 
IgE strata are shown in Fig. 1, panels a, c, and d. Ten of 
the 41 patients (24%) reached values beyond the limit of 
their own baseline  sIgEtot subgroup during at least one 
of the follow-up visits. Of these 10 patients, 4 were in 
the low, 4 in the intermediate, and 2 in the high  sIgEtot 
subgroup, therefore representing 40% of the patients 
in the low  sIgEtot subgroup, 20% of the patients in the 
intermediate  sIgEtot subgroup and 18% of the patients in 
the high  sIgEtot, respectively.
Two patients had  sIgEtot levels in the three categories 
over the 1 year period of observation. One patient initially 
in the low sIgE group had a rise in IgE above 700 IU/mL 
for at least 2 consecutive measurements before returning 
to intermediate levels at the two last visits (Fig. 1b). This 
patient was subsequently found to have developed a 
parasitic infection.
The relevant clinical data for this patient are presented 
in Table  3. The patient did not have any positive RAST 
results at baseline and was therefore considered 
non-atopic.
Relationship between variation in  sIgEtot 
and demographics, environmental exposure 
and treatment features
Age was a significant predictor of  sIgEtot levels over 
12 months.  sIgEtot decreased by 3% with each additional 
year of age (p = 0.01). Allergen exposure for patients 
with a history of a positive RAST test was associated 
with change in  sIgEtot. Exposure scores ranged from 0 to 
12 and reflected the sum of the frequencies of exposure 
for the different allergens for which the patient had 
shown a positive RAST. A unit increase in the exposure 
score was associated with a 5% rise  sIgEtot (p = 0.002). 
No relationship was found between  sIgEtot and gender, 
smoke exposure, and asthma treatment.
Relationship between  sIgEtot and lung function, asthma 
control, and exacerbation
There was no relationship between lung function (% 
predicted FEV1) and  sIgEtot variation at baseline or 
throughout the study period. The odds of severe asthma 
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Table 1 Baseline characteristics stratified by sIgEtot group (low, intermediate, high)
BMI, Body Mass Index; D. pteronyssinus, Dermatophagoides pteronyssinus; FEV1, forced expiratory volume in 1 s; GERD, gastroesophageal reflux disease; ICS, 
inhaled corticosteroids; ICS/LABA, inhaled corticosteroids/long-acting β2 agonists; LABA, long-acting β2 agonists; LTRA, leukotriene receptor antagonist; OCS, oral 
corticosteroids; RAST, radio-allergo sorbent test; SD, standard deviation; SABA, short-acting β2 agonists; SABA/SAAC, short-acting anticholinergic
* p-value < 0.05 were considered statistically significant; ** Regression analysis for age/Fisher’s exact for other (categorical) variables; *** Tukey test for age/general 
linear model with contrasts for other (categorical) variables, the column indicates between which groups were observed the statistical differences: 1 = low  sIgEtot 
subgroup, 2 = intermediate  sIgEtot subgroup and 3 = high  sIgEtot subgroup
Baseline characteristics (N = 41) Low IgE group 
(< 76 IU/mL) 
(N = 10)
Intermediate IgE group 
(76–700 IU/mL) (N = 20)
High IgE group 
(> 700 IU/mL) 
(N = 11)
p value** Difference specification***
Age (years)
 Mean (± SD) 57.7 ± 15.7 49.5 ± 14.7 40.4 ± 13.4 0.03* 1 vs 3
Gender
 Male 5 (29%) 8 (47%) 4 (24%) 0.84
 Female 5 (21%) 12 (50%) 7 (29%)
Race
 Caucasian 10 (28%) 19 (53%) 7 (19%) 0.03* 1 vs 3; 2 vs 3
 Other 0 (0%) 1 (20%) 4 (80%)
Smoking status
 Never smoked 6 (26%) 12 (52%) 5 (22%) 0.27
 Former smoker 3 (25%) 7 (58%) 2 (17%)
 Current smoker 1 (17%) 1 (17%) 4 (66%)
BMI (kg/m2)
 < 30 9 (25%) 17 (47%) 10 (28%) 0.79
 ≥ 30 1 (25%) 3 (75%) 0 (0%)
Medical history
 Allergic rhinitis 2 (9%) 13 (56%) 8 (35%) 0.02* 1 vs 3; 1 vs 2
 Atopic dermatitis 3 (17%) 11 (61%) 4 (22%) 0.33
 GERD 4 (44%) 4 (44%) 1 (11%) 0.23
 Nasal polyps 2 (25%) 3 (38%) 3 (38%) 0.59
Residence
 City 4 (18%) 10 (45%) 8 (36%) 0.51
 Suburbs 4 (40%) 5 (50%) 1 (10%)
 Rural/country 2 (22%) 5 (56%) 2 (22%)
GINA level of asthma control
 Controlled 3 (21%) 8 (57%) 3 (21%) 0.39
 Partly controlled 2 (18%) 7 (64%) 2 (18%)
 Uncontrolled 5 (33%) 4 (27%) 6 (40%)
Positive RAST testing
 D. pteronyssinus 4 (18%) 11 (50%) 7 (32%) 0.65
 Grass mix 4 (22%) 6 (33%) 8 (44%) 0.07 2 vs 3
 Cat dander 2 (12%) 10 (59%) 5 (29%) 0.41
 Dog dander 2 (12%) 7 (44%) 7 (44%) 0.16
 Birch 0 (0%) 5 (42%) 7 (58%) 0.005* 1 vs 3; 2 vs 3; 2 vs 3
 Mold 1 (8%) 5 (42%) 6 (50%) 0.1
Treatment
 ICS/LABA 10 (24%) 20 (49%) 11 (27%) –
 SABA 5 (18%) 18 (64%) 5 (18%) 0.02* 1 vs 2; 2 vs 3
 LTRA 2 (10%) 12 (60%) 6 (30%) 0.11
 OCS 1 (13%) 3 (37%) 4 (50%) 0.34
 SABA/SAAC 1 (33%) 1 (33%) 1 (33%) 1
 LABA 0 (0%) 1 (100%) 0 (0%) 1
Asthma status
 % Predicted FEV1—mean (SD) 72.3 ± 28.6 86.6 ± 18.6 80.2 ± 12.2 0.20
 ACQ total score—median (range) 12.0 (2.0–14.0) 8.0 (5.0–13.0) 8.0 (4.0–13.0) 0.77
 Exhaled nitric oxide—median (range) 15.6 (7.1–46.7) 20.8 (9.6–154.0) 120.9 (5.7–236.0) 0.82
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exacerbations the year prior to enrollment were not 
correlated significantly with baseline  sIgEtot in the 
total study group (OR = 0.95; p = 0.21), nor in the low 
(OR = 0.85; p = 0.95), intermediate (OR = 0.82; p = 0.42) 
or high subgroup (OR = 0.96; p = 0.31). Over the entire 
study period, there was no correlation between  sIgEtot 
and severe exacerbations since the previous visit nor with 
exacerbation that occurred the week before the visits. 
At baseline there was no relationship between sIgE and 
 ACQ6 in the whole group (Spearman’s ρ = 0.01, p = 0.96) 
nor in any of the three groups. There was a significant but 
weak correlation between  sIgEtot and  ACQ6 score across 
all time points (r = 0.15, p = 0.02).
Influence of seasons on  sIgEtot asthma control
Figure  2 shows the variation in  sIgEtot (panel a) and 
asthma control (panel b) according to the seasons. In 
the total study group, there was no association between 
seasons (March–May, June–August; September–
November; December–February) and  sIgEtot (p = 0.47) or 
 ACQ6 score (p = 0.43).
Discussion
There are limited data in the literature on the stability 
of IgE measurements over time in asthmatics. In the 
current study, we investigated variations in  sIgEtot in 
severe asthmatics over a 1  year period with repeated 
measurements every 2  months. The principal finding is 
Table 2 Intra-cluster correlation (ICC) of  serum total 
IgE  (sIgEtot) evaluated over  the  12-month study period 
in  three strata of  asthmatic patients based on   sIgEtot 
at  baseline: < 76  IU/mL (n = 10); 76–700  IU/mL (n = 20) 
and > 700 IU/mL (n = 11)
CI, confidence interval
* Between-patient variability/(between- + within-patient variability)** likelihood 
ratio test comparing within-patient variabilities
ICC (95% CI) (*) 1-ICC (95% CI) p-value (**)
< 76 IU/mL 96 (93–98) % 4 (2–7) %
76–700 IU/mL 71 (62–82) % 29 (18–38) % < 0.0001
> 700 IU/mL 96 (94–99) % 4 (1–6) %
Fig. 1 The 12-month variability in  sIgEtot in severe asthmatic patients stratified by  sIgEtot at baseline (low, intermediate and high). The 12-month 
variability in  sIgEtot was evaluated in 41 patients divided post hoc in three strata based on  sIgEtot at baseline: < 76 IU/mL (n = 10) (a); 76–700 IU/
mL (n = 20) (c) and > 700 IU/mL (n = 11) (d). One outliner patient from the low  sIgEtot group is shown separately (b). The gray zone indicates the 
76–700 IU/mL region (intermediate group) to allow for the identification of patients whose  sIgEtot reached the level of a different group during the 
study period
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that most of the variability  sIgEtot was due to between-
patient variability whereas within-patient variability 
of  sIgEtot levels was rather limited.  sIgEtot was found to 
decrease with age.
The relative stability in  sIgEtot suggests that the 
mechanisms regulating IgE levels are sustained over time 
in most patients. Nonetheless, 24% of patients showed 
 sIgEtot level scores beyond the range of their own group 
for at least one visit. This was particularly the case in 
patients with baseline  sIgEtot < 76  IU/mL as 4 out of 10 
patients had a measurement above 76  IU/mL in at least 
one subsequent blood sample.
Omalizumab is a biologic with proven efficacy to 
improve asthma quality of life and reduce asthma 
exacerbations in severe allergic asthmatics. The findings 
from our study suggest that regular monitoring of  sIgEtot 
in routine clinical practice may assist in optimizing 
treatment by aligning it with observed variations in 
 sIgEtot and thus avoid under-treatment with omalizumab. 
As the 40% of patients with  sIgEtot < 76 IU/mL at baseline 
but subsequent serum levels in the 76–700 IU/mL range 
underscore, without repeated blood sampling these 
patients might not have been initiated on omalizumab, 
which may have translated into a subsequent preventable 
need for corticosteroid therapy or into preventable 
exacerbations and hospitalizations. Likewise, the 20% 
of patients with  sIgEtot between 700 and 1000  IU/
mL who subsequently showed serum levels below the 
700  IU/mL threshold might not have been initiated on 
omalizumab without repeated testing. However, patients 
with very high serum IgE levels (> 2000  IU/mL) remain 
fairly stable in this “high” zone. Although between-
patient variability was the major trend identified in our 
study, limited within-patient variability was still present. 
Therefore, regular monitoring of sIgE over 1 year results 
in an increase from 50 to 66% of patients falling into the 
range between 76 and 700  IU/mL. The limited patient 
variability resulted in the fact that two-third (27/41) 
of our patients treated with high doses ICS/LABA had 
a serum IgE values between 76 and 700  IU/mL after a 
1 year period of observation (including 7 measurements 
for most of them), a figure clearly higher than 50% of 
patients as observed at baseline.
Despite the limited within–patient variability, 
one patient with baseline  sIgEtot < 76  IU/mL showed 
significant changes in serum levels over the observation 
period. This patient who was non-atopic, maintained low 
IgE levels (< 76 IU/mL) at the first two visits, after which 
there was a marked increase to 818  IU/mL at the third 
and 1159  IU/mL at the fourth visit, before declining at 
subsequent visits without, however, returning to low 
serum levels. This patient was a severe corticosteroid-
dependent asthmatic in whom a parasitic infection was 
detected and treated accordingly. Remarkably, when 
the  sIgEtot increased sharply at visit 3, the patient’s 
 ACQ6 scores rose from 2.3 to 4.2 without any change 
in  FEV1 but with an augmentation of the OCS dose as 
treatment adjustment. This case points at the importance 
of considering possible etiologies when a sharp rise in 
IgE is detected. IgE levels are known to increase in the 
case of parasitic infection, namely helminth infections 
[13]; yet other causes of elevated IgE outside an atopic 
status should also be considered including infections 
by mycobacterium tuberculosis, Epstein–Barr virus, 
cytomegalovirus, malignancies, or chronic inflammatory/
dysimmune disorders [14].
Table 3 Clinical data for the outliner patient belonging to the low serum total IgE (sIgEtot) subgroup (see Fig. 1b)
FEV1, forced expiratory volume in 1 s; FENO, fractional exhaled nitric oxide; OCS, oral corticosteroids
Visit Baseline 1 2 3 4 5 6
sIgEtot (IU/mL) 61.3 41 43 818 1159 357 266
FEV1 predicted (%) 49 61 64 52 59 65
Total ACQ score 13 19 14 25 19 15 16
FENO (ppm) 7.1 4.8 18.6 28.1
Asthma exacerbation x x x x x




 Budesonide/formoterol (µg/days) 1200/54 1200/54 800/36 1200/54 1200/54 1200/54 1200/54
 OCS dosis (mg/days) 16 16 8 16 16 16 16
 Beclamethasone/formoterol 200/18 200/18 200/18 200/18
 Salbutamol x x x
 Fenoterol/ipratropium x
 Theophylline x x x x x
 Azythromycine x x x
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Though not powered for that purpose, our study 
also showed an inverse relationship between age and 
serum IgE, a finding we have recently reported in a 
large cross-sectional study in asthmatics [15] and which 
was previously established in longitudinal population 
studies [5, 6]. A decrease in  sIgEtot by 3% with every year 
Fig. 2 Variation in  sIgEtot and asthma control in severe asthmatic patients (n = 41) according to the seasons. Data from the 6 follow-up visits 
are shown according to the month of the visit (the baseline data are not included). In these graphics, the geometric mean  sIgEtot with standard 
deviation (SD) (a) and the geometric mean six-item Juniper Asthma Control Questionnaire  (ACQ6) score with SD (b) are given
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increase in age was observed in the present study. Not 
unexpectedly, allergen exposure score was associated 
with a rise of  sIgEtot in sensitized subjects, supporting a 
role for allergen exposure in IgE synthesis in addition to 
its role in mast cell activation thereby confirming a recent 
study [9].
In contrast to what is known for eosinophils [16, 
17], there are limited data on the relationship between 
 sIgEtot and asthma control and severity. A higher  sIgEtot 
level in severe asthmatics as compared to that in mild 
to moderate asthmatics has recently been reported in a 
large real-life cross-sectional study even if there was a 
considerable overlap between the groups [15]. In the same 
study, there was however no correlation between  ACQ7 
and serum IgE. In the study reported here, though not 
present at baseline, a weak but significant correlation was 
observed between  sIgEtot and  ACQ6 score throughout 
the study period, which suggests that fluctuation in IgE 
over time in a subject may relate to day-to-day asthma 
symptoms. By contrast, no relationship was found 
between  sIgEtot and severe exacerbation rates. Recent 
data from SARP (Severe Asthma Research Program) have 
shown an inverse and surprising relationship between 
serum IgE and propensity to severe exacerbation in 
asthmatics [18].
Omalizumab convincingly reduces asthma 
exacerbation in clinical trial and routine practice in 
patients with serum IgE ranging from 30 to 700  IU/
mL. The efficacy of omalizumab was shown when free 
circulating IgE was reduced by more than 95% and 
maintained at lower than 30  IU/mL [19]; however, 
 sIgEtot itself prior to treatment initiation does not 
predict the ability of the drug to prevent exacerbation 
[20]. Rather than considering the baseline IgE level, 
the IgE level at which omalizumab is able to maintain 
free circulating IgE may be more relevant in terms of 
reduction in exacerbations. It is also likely that airway 
(and not serum) IgE, which can be assessed in sputum 
[4, 21] and bronchial biopsies [22, 23], plays a more 
important role in the disease than circulating IgE 
though a convincing correlation was reported between 
serum and sputum IgE levels [4]. We might have found 
a stronger relationship between IgE and exacerbation if 
we had measured airway IgE rather than serum IgE in 
the present study.
The main limitation of our study is the limited number 
of patients included and followed up throughout the 
protocol. This may have resulted in a lack of association 
between sIgE and seasons in contrast to what was 
reported by others [9]. Moreover, we did not found a 
relationship between smoke exposure and serum IgE. 
Our negative finding does not preclude, however, any 
real effect of smoke exposure on serum IgE because 
of the limited number of current smoking asthmatics 
in our cohort. Future studies with larger sample 
sizes are needed to confirm our findings and explore 
associations with other possible determinants of IgE 
variation. Asthmatics in this study were selected on the 
basis of disease severity defined by the requirement of 
high-dose ICS combined with a LABA. Therefore, the 
IgE variability depicted here may not be applicable to a 
population of mild untreated asthmatics. As we did not 
have detailed history data regarding atopic dermatitis 
we could not assess the influence of the disease 
evolution on  sIgEtot over the study period; specifically, 
whether change in atopic dermatitis severity may have 
influenced change in serum IgE in our study. In our 
study the majority of patients with atopic dermatitis 
were in the intermediate IgE group.
We conclude that in severe asthmatics receiving high-
dose ICS combined with a LABA, there was limited 
within-patient variability of  sIgEtot but significant 
between-patient variability. Yet 30% of the patients not 
initially eligible for receiving omalizumab based on a 
single measurement may actually benefit from repeated 
measurements to qualify for treatment.
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